Childhood and adolescence are important periods for bone development. Any disease that affects bone health has the potential to affect the bones not only in the short term but also later in life. Bone health abnormalities in patients with inflammatory bowel disease are being increasingly recognized. Screening the at-risk patient is important so that appropriate treatments can be instituted. Treatment options are limited to vitamin D and calcium supplementation, control of underlying disease activity, and appropriate physical activity. The role of bisphosphonates in these patients needs to be better studied, and treatment with bisphosphonates may be considered for some patients in consultation with a bone health expert.
BaileyDAMckayHAMirwaldRLCrockerPRFaulknerRA. A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the university of Saskatchewan bone mineral accrual study. J Bone Miner Res. 1999;14:1672-1679.
2.
SemeaoEJJawadAFStoufferNOZemelBSPiccoliDAStallingsVA. Bone mineral density in children and young adults with Crohn’s disease. Inflamm Bowel Dis. 1999;5:161-166.
3.
DubnerSEShultsJBaldassanoRN. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn’s disease. Gastroenterology. 2009;136:123-130.
4.
SylvesterFAWyzgaNHyamsJS. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:42-50.
5.
GilbertLHeXFarmerP. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology. 2000;141:3956-3964.
6.
LeeSEChungWJKwakHB. Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem. 2001;276:49343-49349.
7.
KongYYFeigeUSarosiI. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304-309.
8.
WalshMCChoiY. Biology of the TRANCE axis. Cytokine Growth Factor Rev. 2003;14:251-263.
9.
KudoOSabokbarAPocockAItonagaIFujikawaYAthanasouNA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003;32:1-7.
10.
GilbertLHeXFarmerP. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem. 2002;277:2695-2701.
11.
RadeffJMNagyZSternPH. Involvement of PKC-beta in PTH, TNF-alpha, and IL-1 beta effects on IL-6 promoter in osteoblastic cells and on PTH-stimulated bone resorption. Exp Cell Res. 2001;268:179-188.
12.
PereiraRCDelanyAMCanalisE. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone. 2002;30:685-691.
13.
CanalisEBilezikianJPAngeliAGiustinaA. Perspectives on glucocorticoid-induced osteoporosis. Bone. 2004;34:593-598.
14.
AbreuMTGellerJLVasiliauskasEA. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn’s disease. J Clin Gastroenterol. 2006;40:55-63.
15.
BernsteinMIrwinSGreenbergGR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn’s disease. Am J Gastroenterol. 2005;100:2031-2035.
16.
ThayuMLeonardMBHyamsJS. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn’s disease: results of the REACH study. Clin Gastroenterol Hepatol. 2008;6:1378-1384.
17.
SzulcPChapuyMCMeunierPJDelmasPD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest. 1993;91:1769-1774.
18.
HildebrandHKarlbergJKristianssonB. Longitudinal growth in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1994;18:165-173.
19.
BurnhamJMShultsJSemeaoE. Body-composition alterations consistent with cachexia in children and young adults with Crohn disease. Am J Clin Nutr. 2005;82:413-420.
20.
BurnhamJMShultsJSemeaoE. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res. 2004;19:1961-1968.
21.
ThayuMShultsJBurnhamJM. Gender differences in body composition deficits at diagnosis in children and adolescents with Crohn’s disease. Inflamm Bowel Dis. 2007;13:1121-1128.
22.
ThayuMShultsJBurnhamJMZemelBSBaldassanoRNLeonardMB. Risk factors for low bone mineral density in children and young adults with Crohn’s disease. J Pediatr. 1999;135:593-600.
23.
PollakRDKarmeliFEliakimRAckermanZTabbKRachmilewitzD. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93:1483-1490.
24.
BischoffSCHerrmannAGökeMMannsMPvon zur MühlenABrabantG. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol. 1997;92:1157-1163.
25.
SemeaoEStallingsVPeckSPiccoliD. Vertebral compression fractures in pediatric patients with Crohn’s disease. Gastroenterology. 1997;112:1710-1713.
26.
ThearleMHorlickMBilezikianJP. Osteoporosis: an unusual presentation of childhood Crohn’s disease. J Clin Endocrinol Metab. 2000;85:2122-2126.
27.
van StaaTPCooperCBrusseLSLeufkensHJavaidMKArdenNK. Inflammatory bowel disease and the risk of fracture. Gastroenterology. 2003;125:1591-1597.
28.
BernsteinCNBlanchardJFLeslieWWajdaAYuBN. The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med. 2000;133:795-799.
29.
LoftusEVJrCrowsonCSSandbornWJTremaineWJO’FallonWMMeltonLJIII. Long-term fracture risk in patients with Crohn’s disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002;123:468-475.
30.
GafniRIBaronJ. Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy x-ray absorptiometry (DEXA). J Pediatr. 2004;144:253-257.
31.
StephensMBatresLANgDBaldassanoR. Growth failure in the child with inflammatory bowel disease. Semin Gastrointest Dis. 2001;12:253-262.
32.
GilsanzV. Bone density in children: a review of the available techniques and indications. Eur J Radiol. 1998;26:177-182.
33.
BaimSLeonardMBBianchiML. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom. 2008;11:6-21.
34.
FellJMPaintinMArnaud-BattandierF. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Chrohn’s disease. Aliment Pharmacol Ther. 2000;14:281-289.
35.
BorrelliOCordischiLCirulliM. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4:744-753.
36.
NewbyEASawczenkoAThomasAGWilsonD. Interventions for growth failure in childhood Crohn’s disease. Cochrane Database Syst Rev. 2005;(3):CD003873.
37.
CadoganJEastellRJonesNBarkerME. Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial. BMJ. 1997;315:1255-1260.
38.
BonjourJPCarrieALFerrariS. Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest. 1997;99:1287-1294.
39.
AlaimoKMcDowellMABriefelRR. Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988-91. Adv Data. 1994;(258):1-28.
40.
BenchimolEIWardLMGallagherJC. Effect of calcium and vitamin D supplementation on bone mineral density in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45:538-545.
41.
SpeckerBBinkleyT. Randomized trial of physical activity and calcium supplementation on bone mineral content in 3- to 5-year-old children. J Bone Miner Res. 2003;18:885-892.
42.
SpeckerBL. Evidence for an interaction between calcium intake and physical activity on changes in bone mineral density. J Bone Miner Res. 1996;11:1539-1544.
43.
Iuliano-BurnsSSaxonLNaughtonGGibbonsKBassSL. Regional specificity of exercise and calcium during skeletal growth in girls: a randomized controlled trial. J Bone Miner Res. 2003;18:156-162.
44.
MisraMPacaudDPetrykACollett-SolbergPFKappyM. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008;122:398-417.
45.
WagnerCLGreerFR. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics. 2008;122:1142-1152.
46.
Food and Nutrition Board. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. In: Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Washington, DC: National Academy Press; 1997.
47.
PeterlikMCrossHS. Vitamin D and calcium insufficiency-related chronic diseases: molecular and cellular pathophysiology. Eur J Clin Nutr. 2009;63:1377-1386.
48.
HeaneyRPDowellMSHaleCABendichA. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr. 2003;22:142-146.
49.
HeaneyRPDaviesKMChenTCHolickMFBarger-LuxMJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77:204-210.
50.
ArmasLAHollisBWHeaneyRP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004;89:5387-5391.
51.
GordonCMWilliamsALFeldmanHA. Treatment of hypovitaminosis D in infants and toddlers. J Clin Endocrinol Metab. 2008;93:2716-2721.
52.
KuwabaraKMatsudaSFushimiKIshikawaKBHoriguchiHFujimoriK. Hospital volume and quality of laparoscopic gastrectomy in Japan. Dig Surg. 2009;26:422-429.
53.
ParfittAM. The two faces of growth: benefits and risks to bone integrity. Osteoporos Int. 1994;4:382-398.
54.
JanzKF. Validation of the CSA accelerometer for assessing children’s physical activity. Med Sci Sports Exerc. 1994;26:369-375.
55.
BassSPearceGBradneyM. Exercise before puberty may confer residual benefits in bone density in adulthood: studies in active prepubertal and retired female gymnasts. J Bone Miner Res. 1998;13:500-507.
56.
BassSLSaxonLDalyRM. The effect of mechanical loading on the size and shape of bone in pre-, peri-, and postpubertal girls: a study in tennis players. J Bone Miner Res. 2002;17:2274-2280.
57.
BassSPearceGYoungNSeemanE. Bone mass during growth: the effects of exercise. Exercise and mineral accrual. Acta Univ Carol Med (Praha). 1994;40:3-6.
58.
LloydTPetitMALinHMBeckTJ. Lifestyle factors and the development of bone mass and bone strength in young women. J Pediatr. 2004;144:776-782.
59.
LloydTChinchilliVMJohnson-RollingsNKieselhorstKEggliDFMarcusR. Adult female hip bone density reflects teenage sports-exercise patterns but not teenage calcium intake. Pediatrics. 2000;106:40-44.
60.
RobinsonRJKrzywickiTAlmondL. Effect of a low-impact exercise program on bone mineral density in Crohn’s disease: a randomized controlled trial. Gastroenterology. 1998;115:36-41.
61.
RauchFPlotkinHZeitlinLGlorieuxFH. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res. 2003;18:610-614.
62.
GlorieuxFHBishopNJPlotkinHChabotGLanoueGTraversR. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947-952.
63.
GlorieuxFH. Bisphosphonate therapy for severe osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2000;13(suppl 2):989-992.
64.
WirthSMLawsonAPSutphinSDAdamsVRSmithKM. Osteonecrosis of the jaw associated with bisphosphonate therapy. Orthopedics. 2009;32:900-903.
65.
WHO Study Group. Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Geneva, Switzerland: World Health Organization; 1994.
